Differential restoration of functional hyperemia by antihypertensive drug classes in hypertension-related cerebral small vessel diseases
Harraz, Osama F
Longden, Thomas A
Ferris, Hannah R
Wellman, George C
Hill-Eubanks, David C
Greenstein, Adam S
JournalJournal of Clinical Investigation
PublisherAmerican Society for Clinical Investigation
MetadataShow full item record
AbstractDementia resulting from small vessel diseases of the brain (SVDs) is an emerging epidemic for which there is no treatment. Hypertension is the major risk factor for SVDs, but how hypertension damages the brain microcirculation is unclear. Here, we show that chronic hypertension in a mouse model progressively disrupts on-demand delivery of blood to metabolically active areas of the brain (functional hyperemia) through diminished activity of the capillary endothelial cell inward-rectifier potassium channel, Kir2.1. Despite similar efficacy in reducing blood pressure, amlodipine, a voltage-dependent calcium-channel blocker, prevented hypertension-related damage to functional hyperemia whereas losartan, an angiotensin II type-1 receptor blocker, did not. We attribute this drug class effect to losartan-induced 'aldosterone breakthrough', a phenomenon triggered by pharmacological interruption of the renin-angiotensin pathway leading to elevated plasma aldosterone levels. This hypothesis is supported by the finding that combining losartan with the aldosterone receptor antagonist eplerenone prevented the hypertension-related decline in functional hyperemia. Collectively, these data suggest Kir2.1 as a possible therapeutic target in vascular dementia and indicate that concurrent mineralocorticoid aldosterone receptor blockade may aid in protecting against late-life cognitive decline in hypertensive patients treated with angiotensin II type-1 receptor blockers.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/16349
- PIP<sub>2</sub> corrects cerebral blood flow deficits in small vessel disease by rescuing capillary Kir2.1 activity.
- Authors: Dabertrand F, Harraz OF, Koide M, Longden TA, Rosehart AC, Hill-Eubanks DC, Joutel A, Nelson MT
- Issue date: 2021 Apr 27
- Improving vascular function in hypertension: potential benefits of combination therapy with amlodipine and renin-angiotensin-aldosterone system blockers.
- Authors: Siragy HM
- Issue date: 2010 Jan
- Clinical implications of aldosterone blockade.
- Authors: Weber MA
- Issue date: 2002 Nov
- Effect of combination therapy with the angiotensin receptor blocker losartan plus hydrochlorothiazide on brain perfusion in patients with both hypertension and cerebral hemodynamic impairment due to symptomatic chronic major cerebral artery steno-occlusive disease: a SPECT study.
- Authors: Saura H, Ogasawara K, Suzuki T, Kuroda H, Yamashita T, Kobayashi M, Terasaki K, Ogawa A
- Issue date: 2012
- Impact of mineralocorticoid receptor blockade with direct renin inhibition in angiotensin II-dependent hypertensive mice.
- Authors: Hashimoto A, Takeda Y, Karashima S, Kometani M, Aono D, Demura M, Higashitani T, Konishi S, Yoneda T, Takeda Y
- Issue date: 2020 Oct